Cara Therapeutics. has been granted a patent for an oral formulation that combines a kappa opioid receptor agonist, specifically CR845, with an oligosaccharide stabilizing agent. This formulation aims to treat conditions associated with kappa opioid receptors, including pain and inflammation, and includes methods for its manufacture and use. GlobalData’s report on Cara Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cara Therapeutics, Tetrapeptide derivatives was a key innovation area identified from patents. Cara Therapeutics's grant share as of June 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
Oral formulation of kappa opioid receptor agonist for treatment
The granted patent US11986509B2 presents a novel formulation designed for the oral delivery of a kappa opioid receptor agonist, specifically CR845. The formulation consists of particles that include CR845 and an oligosaccharide, with the potential to enhance absorption through the inclusion of various absorption enhancers such as sodium caprate, lauroyl L-carnitine, and quaternary ammonium salts. Additionally, the formulation may contain pharmaceutically acceptable components like diluents, excipients, and carriers, as well as other agents such as carboxylic acid salts, binding agents, and chelating agents. Notably, the patent outlines that the carboxylic acid salt can be a citrate salt, with lauroyl L-carnitine serving as an absorption enhancer and ethylenediaminetetraacetic acid as a chelating agent.
The patent further details the various forms in which the formulation can be presented, including tablets, caplets, capsules, powders, slurries, liquid suspensions, or gels, with an emphasis on enteric coating for certain dosage forms. The manufacturing method involves spray drying a mixture of CR845 and trehalose to create the particles. This innovative approach aims to improve the oral bioavailability of CR845, potentially offering a more effective delivery system for therapeutic applications involving kappa opioid receptor modulation.
To know more about GlobalData’s detailed insights on Cara Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
